{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:27:26Z","timestamp":1791404846651,"version":"4.3.3"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Clinical trials have shown that low-dose glucocorticoid therapy in patients with RA reduces bone loss in hands or hip, but the effect on osteoporotic fractures is not yet clear. Therefore, we investigated the use of low-dose oral glucocorticoids and risk of osteoporotic fractures among patients with RA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a cohort study including patients with RA aged 50+\u2009years from the Clinical Practice Research Datalink between 1997 and 2017. Exposure to oral glucocorticoids was stratified by the most recent prescription in current (&amp;lt;6\u2009months), recent (7\u201312\u2009months) and past (&amp;gt;1\u2009year) use, and average daily and cumulative doses. Risk of incident osteoporotic fractures (including hip, vertebrae, humerus, forearm, pelvis and ribs) was estimated by time-dependent Cox proportional-hazards models, adjusted for lifestyle parameters, comorbidities and comedications. Secondary analyses assessed osteoporotic fracture risk with a combination of average daily and cumulative doses of oral glucocorticoids.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 15\u2009123 patients with RA (mean age 68.8\u2009years, 68% females), 1640 osteoporotic fractures occurred. Current low-dose oral glucocorticoid therapy (\u22647.5\u2009mg prednisolone equivalent dose\/day) in patients with RA was not associated with overall risk of osteoporotic fractures (adjusted hazard ratio 1.14, 95% CI 0.98, 1.33) compared with past glucocorticoid use, but was associated with an increased risk of clinical vertebral fracture (adjusted hazard ratio 1.59, 95% CI 1.11, 2.29). Results remained unchanged regardless of a short-term or a long-term use of oral glucocorticoids.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Clinicians should be aware that even in RA patients who receive low daily glucocorticoid doses, the risk of clinical vertebral fracture is increased.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab548","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T19:14:19Z","timestamp":1625858059000},"page":"1448-1458","source":"Crossref","is-referenced-by-count":37,"title":["Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0482-5563","authenticated-orcid":false,"given":"Shahab","family":"Abtahi","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre"},{"name":"Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht"},{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna H M","family":"Driessen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre"},{"name":"Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht"},{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht"},{"name":"NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-8530","authenticated-orcid":false,"given":"Andrea M","family":"Burden","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre"},{"name":"Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C","family":"Souverein","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop P","family":"van den Bergh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht"},{"name":"Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands"},{"name":"Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjeerd P","family":"van Staa","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht"},{"name":"Centre for Health Informatics, Division of Informatics, Imaging and Data Science, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0682-9533","authenticated-orcid":false,"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht"},{"name":"Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre"},{"name":"Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht"},{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht"},{"name":"MRC Epidemiology Lifecourse Unit, Southampton General Hospital, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"2022041112492706300_keab548-B1","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.22117","article-title":"Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis","volume":"54","author":"Van Staa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022041112492706300_keab548-B2","doi-asserted-by":"crossref","first-page":"R154","DOI":"10.1186\/ar3107","article-title":"Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis","volume":"12","author":"Kim","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2022041112492706300_keab548-B3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/ard.60.5.521","article-title":"Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland","volume":"60","author":"Huusko","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"2022041112492706300_keab548-B4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022041112492706300_keab548-B5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"Van Staa","year":"2002","journal-title":"Osteoporos Int"},{"key":"2022041112492706300_keab548-B6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"Van Staa","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2022041112492706300_keab548-B7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","article-title":"Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone","volume":"102","author":"Weinstein","year":"1998","journal-title":"J Clin Invest"},{"key":"2022041112492706300_keab548-B8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","article-title":"Glucocorticoid-induced osteoporosis: an update","volume":"61","author":"Compston","year":"2018","journal-title":"Endocrine"},{"key":"2022041112492706300_keab548-B9","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archinte.165.11.1293","article-title":"Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial","volume":"165","author":"Haugeberg","year":"2005","journal-title":"Arch Intern Med"},{"key":"2022041112492706300_keab548-B10","doi-asserted-by":"crossref","first-page":"R128","DOI":"10.1186\/ar2542","article-title":"Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study","volume":"10","author":"Engvall","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"2022041112492706300_keab548-B11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/ard.48.7.535","article-title":"Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study","volume":"48","author":"Sambrook","year":"1989","journal-title":"Ann Rheum Dis"},{"key":"2022041112492706300_keab548-B12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/03009740701394021","article-title":"Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density","volume":"36","author":"Tengstrand","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"2022041112492706300_keab548-B13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/nyas.12446","article-title":"Bone safety of low-dose glucocorticoids in rheumatic diseases","volume":"1318","author":"Saag","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"2022041112492706300_keab548-B14","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/ard.62.11.1033","article-title":"Glucocorticoids in the treatment of early and late RA","volume":"62","author":"Bijlsma","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2022041112492706300_keab548-B15","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/jbmr.3523","article-title":"Glucocorticoid exposure and fracture risk in a cohort of US patients with selected conditions","volume":"33","author":"Balasubramanian","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2022041112492706300_keab548-B16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bone.2018.09.004","article-title":"The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: a cohort study","volume":"117","author":"Robinson","year":"2018","journal-title":"Bone"},{"key":"2022041112492706300_keab548-B17","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022041112492706300_keab548-B18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"key":"2022041112492706300_keab548-B19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/1099-1557(200009\/10)9:5<359::AID-PDS507>3.0.CO;2-E","article-title":"The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results","volume":"9","author":"Van Staa","year":"2000","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022041112492706300_keab548-B20","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.3399\/bjgp10X483562","article-title":"Validity of diagnostic coding within the General Practice Research Database: a systematic review","volume":"60","author":"Khan","year":"2010","journal-title":"Br J Gen Pract"},{"key":"2022041112492706300_keab548-B21","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.24015","article-title":"How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database?","volume":"59","author":"Thomas","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2022041112492706300_keab548-B22","doi-asserted-by":"crossref","first-page":"e009309","DOI":"10.1136\/bmjopen-2015-009309","article-title":"An algorithm to identify rheumatoid arthritis in primary care: a Clinical Practice Research Datalink study","volume":"5","author":"Muller","year":"2015","journal-title":"BMJ Open"},{"key":"2022041112492706300_keab548-B23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/art.22294","article-title":"Fracture risk with intermittent high-dose oral glucocorticoid therapy","volume":"56","author":"De Vries","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2022041112492706300_keab548-B24"},{"key":"2022041112492706300_keab548-B25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/annrheumdis-2020-218758","article-title":"Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study","volume":"80","author":"Abtahi","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022041112492706300_keab548-B26"},{"key":"2022041112492706300_keab548-B27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"2022041112492706300_keab548-B28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/9781118344828","volume-title":"Textbook of pharmacoepidemiology","author":"Strom","year":"2013","edition":"edn."},{"key":"2022041112492706300_keab548-B29","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/archinte.164.4.420","article-title":"Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls","volume":"164","author":"\u00d8rstavik","year":"2004","journal-title":"Arch Intern Med"},{"key":"2022041112492706300_keab548-B30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11657-018-0424-x","article-title":"Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study","volume":"13","author":"Amiche","year":"2018","journal-title":"Arch Osteoporos"},{"key":"2022041112492706300_keab548-B31","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"2022041112492706300_keab548-B32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2022041112492706300_keab548-B33"},{"key":"2022041112492706300_keab548-B34","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s00198-004-1702-6","article-title":"Epidemiology of osteoporotic fractures","volume":"16","author":"Johnell","year":"2005","journal-title":"Osteoporos Int"},{"key":"2022041112492706300_keab548-B35","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s00198-019-05109-0","article-title":"Secular trends in major osteoporotic fractures among 50+ adults in Denmark between 1995 and 2010","volume":"30","author":"Abtahi","year":"2019","journal-title":"Osteoporos Int"},{"key":"2022041112492706300_keab548-B36","doi-asserted-by":"crossref","first-page":"30S","DOI":"10.1016\/S0002-9343(97)90025-5","article-title":"Clinical consequences of vertebral fractures","volume":"103","author":"Ross","year":"1997","journal-title":"Am J Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab548\/39773504\/keab548.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/4\/1448\/43355977\/keab548.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/4\/1448\/43355977\/keab548.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T12:52:43Z","timestamp":1649681563000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/4\/1448\/6320799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,7,13]]},"published-print":{"date-parts":[[2022,4,11]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab548","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,7,13]]}}}